These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9818065)

  • 21. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
    David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
    Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advance of several types of important marine antitumor drugs].
    Zhang JY; Fu LW
    Yao Xue Xue Bao; 2008 May; 43(5):435-42. PubMed ID: 18717327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
    Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
    J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
    Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
    [No Abstract]   [Full Text] [Related]  

  • 25. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
    Valoti G; Nicoletti MI; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
    Clin Cancer Res; 1998 Aug; 4(8):1977-83. PubMed ID: 9717828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
    Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
    van Kesteren C; Twelves C; Bowman A; Hoekman K; López-Lázaro L; Jimeno J; Guzman C; Mathôt RA; Simpson A; Vermorken JB; Smyth J; Schellens JH; Hillebrand MJ; Rosing H; Beijnen JH
    Anticancer Drugs; 2002 Apr; 13(4):381-93. PubMed ID: 11984084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids.
    Martinez EJ; Corey EJ
    Org Lett; 1999 Jul; 1(1):75-7. PubMed ID: 10822537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New therapeutic strategies for soft tissue sarcomas.
    von Mehren M
    Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
    Wright BJ; Chan C; Danishefsky SJ
    J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies directed to the total synthesis of ET 743 and analogues thereof: an expeditious route to the ABFGH subunit.
    Zhou B; Guo J; Danishefsky SJ
    Org Lett; 2002 Jan; 4(1):43-6. PubMed ID: 11772086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique features of the mode of action of ET-743.
    D'Incalci M; Erba E; Damia G; Galliera E; Carrassa L; Marchini S; Mantovani R; Tognon G; Fruscio R; Jimeno J; Faircloth GT
    Oncologist; 2002; 7(3):210-6. PubMed ID: 12065793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in the clinical development of new marine-derived anticancer compounds.
    Jimeno J; López-Martín JA; Ruiz-Casado A; Izquierdo MA; Scheuer PJ; Rinehart K
    Anticancer Drugs; 2004 Apr; 15(4):321-9. PubMed ID: 15057135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for drug combinations.
    Smyth JF
    Eur J Cancer; 2003 Sep; 39(13):1816-7. PubMed ID: 12932657
    [No Abstract]   [Full Text] [Related]  

  • 36. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
    Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
    Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
    Cuevas C; Francesch A
    Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
    Tognon G; Frapolli R; Zaffaroni M; Erba E; Zucchetti M; Faircloth GT; D'Incalci M
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):89-90. PubMed ID: 14586558
    [No Abstract]   [Full Text] [Related]  

  • 39. New activities for the anti-tumor agent trabectedin: taking two birds with one stone.
    D'Incalci M; Frapolli R; Germano G; Allavena P
    Oncotarget; 2013 Apr; 4(4):496-7. PubMed ID: 23625743
    [No Abstract]   [Full Text] [Related]  

  • 40. Science and serendipity in cancer research.
    Smyth JF
    Eur J Cancer; 2001 Jan; 37(1):8. PubMed ID: 11165123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.